These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 12720218

  • 1. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K.
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [Abstract] [Full Text] [Related]

  • 4. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, de Witte T, Dolstra H, Raymakers R.
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [Abstract] [Full Text] [Related]

  • 5. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Mar; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.
    Transplantation; 2009 Dec 15; 88(11):1312-8. PubMed ID: 19996931
    [Abstract] [Full Text] [Related]

  • 7. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 8. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D.
    Bone Marrow Transplant; 2004 Jul 20; 34(1):77-84. PubMed ID: 15133485
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 20; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 10. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
    Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF.
    Bone Marrow Transplant; 2001 Aug 20; 28(4):335-9. PubMed ID: 11571504
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S.
    Biol Blood Marrow Transplant; 2008 Jan 20; 14(1):50-8. PubMed ID: 18158961
    [Abstract] [Full Text] [Related]

  • 13. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
    Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD.
    Bone Marrow Transplant; 2002 Apr 20; 29(7):621-4. PubMed ID: 11979314
    [Abstract] [Full Text] [Related]

  • 14. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan 20; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
    Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D.
    Bone Marrow Transplant; 2002 Jul 20; 30(2):95-102. PubMed ID: 12132048
    [Abstract] [Full Text] [Related]

  • 16. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A, German Study-group Multiple Myeloma (DSMM).
    Bone Marrow Transplant; 2003 Jun 20; 31(11):973-9. PubMed ID: 12774047
    [Abstract] [Full Text] [Related]

  • 17. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 Jun 20; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 18. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V.
    Biol Blood Marrow Transplant; 2003 Mar 20; 9(3):189-97. PubMed ID: 12652470
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, Carson E, Eisbruch A, Dawson LA, McDonagh K, Ferrara J, Uberti J.
    Bone Marrow Transplant; 2001 Apr 20; 27(8):801-7. PubMed ID: 11477436
    [Abstract] [Full Text] [Related]

  • 20. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.
    Bone Marrow Transplant; 2005 Mar 20; 35(6):601-8. PubMed ID: 15756285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.